Transcription of Dialysis of Drugs
{{id}} {{{paragraph}}}
Example: stock market
Dialysis of Drugs
2000 Dialysis of DrugsPROVIDED AS AN EDUCATIONAL SERVICE BY AMGEN Dialysis of DrugsCurtis A. Johnson, PharmDMember, Board of DirectorsNephrology Pharmacy AssociatesAnn Arbor, MichiganandProfessor of Pharmacy and MedicineUniversity of Wisconsin-MadisonMadison, WisconsinWilliam D. Simmons,RPhSenior Clinical PharmacistDepartment of PharmacyUniversity of Wisconsin Hospital and ClinicsMadison, WisconsinSEE DISCLAIMER REGARDING USE OF THIS POCKET BOOKIDIALYSIS OF DRUGS4 SEE DISCLAIMER REGARDING USE OF THIS POCKET BOOKDISCLAIMER These Dialysis of Drugs guidelinesare offered as a general summary of informationfor pharmacists and other medical administration of Drugs may involveserious medical risks to the patient which canonly be identified by medical on the circumstances, the risks can be serious and can include severe injury, including death. These guidelines cannot identifymedical risks specific to an individual patient orrecommend patient treatment.
of renal and nonrenal clearance—of a drug is often termed the “plasma clearance” of a drug. In dialysis patients, renal clearance is largely replaced by dialysate clearance. If, for a particular drug, nonrenal clearance is large compared to renal clearance, the contribution dialysis may make to total drug removal is low.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: